<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAE</journal-id>
<journal-id journal-id-type="hwp">sptae</journal-id>
<journal-title>Therapeutic Advances in Endocrinology and Metabolism</journal-title>
<issn pub-type="ppub">2042-0188</issn>
<issn pub-type="epub">2042-0196</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042018812471070</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042018812471070</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories>
<title-group>
<article-title>Vitamin D and rheumatoid arthritis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kostoglou-Athanassiou</surname><given-names>Ifigenia</given-names></name>
<aff id="aff1-2042018812471070">Department of Endocrinology, Red Cross Hospital, 7 Korinthias Street, 115 26 Athens, Greece</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Athanassiou</surname><given-names>Panagiotis</given-names></name>
<aff id="aff2-2042018812471070">Department of Rheumatology, St Paul’s Hospital, Thessaloniki, Greece</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Lyraki</surname><given-names>Aikaterini</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Raftakis</surname><given-names>Ioannis</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Antoniadis</surname><given-names>Christodoulos</given-names></name>
<aff id="aff3-2042018812471070">Department of Rheumatology, Asclepeion Hospital, Athens, Greece</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042018812471070"><email>ikostoglouathanassiou@yahoo.gr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<fpage>181</fpage>
<lpage>187</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-2042018812471070">
<title>Objectives:</title><p>Vitamin D deficiency has been implicated in the pathogenesis of autoimmune diseases, such as diabetes mellitus type 1 and multiple sclerosis. Reduced vitamin D intake has been linked to increased susceptibility to the development of rheumatoid arthritis (RA) and vitamin D deficiency has been found to be associated with disease activity in patients with RA. The objective was to evaluate vitamin D status in patients with RA and to assess the relationship between vitamin D levels and disease activity.</p></sec>
<sec id="section2-2042018812471070">
<title>Methods:</title><p>In a cohort of 44 patients with RA, 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] levels, parathyroid hormone levels, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured. Disease activity was evaluated by calculating the 28-joint Disease Activity Score (DAS28). A control group (<italic>n</italic> = 44), matched for age and sex, was evaluated as well.</p></sec>
<sec id="section3-2042018812471070">
<title>Results:</title><p>In the cohort of 44 patients with RA 25(OH)D<sub>3</sub> levels were found to be low compared with the control group, 25(OH)D<sub>3</sub> being 15.26 ± 1.07 ng/ml [mean ± standard error of the mean (SEM)] and 25.8 ± 1.6 ng/ml in the patient and control group respectively (Student’s t test, <italic>p</italic> &lt; 0.001). Parathyroid hormone levels were 71.08 ± 7.02 pg/ml (mean ± SEM) (normal values 10.0–65.0 pg/ml), CRP 7.6 ± 1.57 mg/litre (mean ± SEM) (normal values &lt; 3 mg/litre) and ESR was 38.0 ± 4.6 mm/h (mean ± SEM) in the group of patients with RA. Levels of 25(OH)D<sub>3</sub> were found to be negatively correlated to the DAS28, the correlation coefficient being −0.084. Levels of 25(OH)D<sub>3</sub> were also found to be negatively correlated to CRP and ESR, the correlation coefficient being <bold>–</bold>0.115 and −0.18, respectively.</p></sec>
<sec id="section4-2042018812471070">
<title>Conclusion:</title><p>It appears that vitamin D deficiency is highly prevalent in patients with RA, and that vitamin D deficiency may be linked to disease severity in RA. As vitamin D deficiency has been linked to diffuse musculoskeletal pain, these results have therapeutic implications. Vitamin D supplementation may be needed both for the prevention of osteoporosis as well as for pain relief in patients with RA.</p></sec>
</abstract>
<kwd-group>
<kwd>disease activity</kwd>
<kwd>rheumatoid arthritis</kwd>
<kwd>vitamin D</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-2042018812471070" sec-type="intro">
<title>Introduction</title>
<p>Vitamin D is a secosteroid hormone involved in bone and calcium metabolism. It is involved in the regulation of calcium homeostasis, as it regulates calcium absorption from the gastrointestinal system [<xref ref-type="bibr" rid="bibr22-2042018812471070">Holick, 2011</xref>]. The hormone is synthesized in the skin by the action of ultraviolet irradiation [<xref ref-type="bibr" rid="bibr29-2042018812471070">Mason <italic>et al</italic>. 2011</xref>]. Vitamin D has extraskeletal effects as well [<xref ref-type="bibr" rid="bibr15-2042018812471070">Fernandes de Abreu <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr20-2042018812471070">Hewison, 2012</xref>]. The nonclassical actions of vitamin D are currently under discussion. Vitamin D has been found to have immunomodulatory actions [<xref ref-type="bibr" rid="bibr5-2042018812471070">Bartley, 2010</xref>; <xref ref-type="bibr" rid="bibr6-2042018812471070">Bikle, 2011</xref>]. Vitamin D deficiency has been shown to be correlated with the appearance of autoimmune diseases, such as diabetes mellitus type 1 and multiple sclerosis [<xref ref-type="bibr" rid="bibr23-2042018812471070">Jankosky <italic>et al</italic>. 2012</xref>].</p>
<p>Rheumatoid arthritis (RA) is an autoimmune disease of unknown aetiology [<xref ref-type="bibr" rid="bibr30-2042018812471070">McInnes and Schett, 2011</xref>]. Both T and B lymphocytes are involved in the pathogenesis of the disease [<xref ref-type="bibr" rid="bibr9-2042018812471070">Choy, 2012</xref>]. The role of T lymphocytes as well as that of B lymphocytes in the pathogenesis of RA has been further proved by the therapeutic efficacy of methods affecting both T and B lymphocytes, namely the biological agents [<xref ref-type="bibr" rid="bibr26-2042018812471070">Keystone <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr34-2042018812471070">Sharma and Pathak, 2012</xref>]. Vitamin D deficiency may increase the risk for the development of RA [<xref ref-type="bibr" rid="bibr31-2042018812471070">Merlino <italic>et al</italic>. 2004</xref>]. Recently, the role of vitamin D deficiency in the pathogenesis of RA, as well as the relationship between vitamin D deficiency and the activity of RA is discussed [<xref ref-type="bibr" rid="bibr35-2042018812471070">Song <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr27-2042018812471070">Kim <italic>et al</italic>. 2012</xref>]. RA is an inflammatory disease characterized by flares and remissions, flares being characterized by pain. Vitamin D deficiency is also known to be associated with diffuse musculoskeletal pain [<xref ref-type="bibr" rid="bibr21-2042018812471070">Hirani, 2012</xref>].</p>
<p>The objective of the study was to evaluate the relationship between vitamin D and RA, as well as the relationship between vitamin D and RA disease activity.</p>
</sec>
<sec id="section6-2042018812471070" sec-type="methods">
<title>Methods</title>
<p>The study cohort consisted of 44 patients with RA. The patients entered the study as they came for evaluation at the Rheumatology Department’s outpatient clinic. All patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism RA classification criteria [<xref ref-type="bibr" rid="bibr2-2042018812471070">Aletaha <italic>et al</italic>. 2010</xref>]. A control group (<italic>n</italic> = 44), matched for age and sex, was evaluated as well. In the cohort of 44 patients with RA, 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] levels, parathyroid hormone levels, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured. Disease activity was evaluated by calculating the 28-joint Disease Activity Score (DAS28). Additionally, the Health Assessment Questionnaire (HAQ) index and the visual analogue scale (VAS) pain score were calculated.</p>
<p>25(OH)D<sub>3</sub> levels were measured by radioimmunoassay using a two-step procedure. The first step involved a rapid extraction of 25(OH)D and other hydroxylated metabolites from serum or plasma with acetonitrile. Following extraction, the treated samples were then assayed by competitive, radioimmunoassay (RIA) using an antibody with specificity to 25OHD. The sample, antibody and tracer were incubated for 90 min at 20–25°C. Phase separation was accomplished after 20 min incubation at 20–25°C with a second antibody precipitating complex. To reduce nonspecific binding, buffer was added after this incubation prior to centrifugation. The final measurement was performed by a gamma counter manufactured by Packard. The sensitivity of the assay was less than 1.6 ng/ml. The recovery was approximately 100% for 25(OH)D<sub>3</sub>. Within and between batch precision was less than 12% and less than 11%, respectively.</p>
<p>Parathyroid hormone was measured by a solid phase two-site immunoradiometric assay, with a sensitivity of 0.7 pg/ml and within assay and between assay coefficient of variation of 7.5% and 6.8% respectively at 5.7 pg/ml.</p>
<p>All patients had a full clinical and laboratory evaluation. The DAS28 score was calculated for all patients. In addition, the HAQ disability index and the VAS pain score were calculated.</p>
<p>Statistical analysis was performed using the statistical package SPSS19. Student’s <italic>t</italic>-test was used to compare the patient group with the control group. Regression analysis was performed to analyze the relationship between indices of disease activity and 25(OH)D<sub>3</sub> levels.</p>
</sec>
<sec id="section7-2042018812471070" sec-type="results">
<title>Results</title>
<p>In the cohort of 44 patients with RA 25(OH)D<sub>3</sub> levels were found to be low compared with the control group, 25(OH)D<sub>3</sub> being 15.26 ± 1.07 ng/ml [mean ± standard error of the mean (SEM)], range 7.00–44.8 ng/ml and 25.8±1.6 ng/ml, range 6.8–80.0 ng/ml in the patient and control group respectively (Student’s <italic>t</italic>-test, <italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig1-2042018812471070">Figure 1</xref>).</p>
<fig id="fig1-2042018812471070" position="float">
<label>Figure 1.</label>
<caption>
<p>25-Hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] levels [ng/ml, mean ± standard error of the mean (SEM)] in the group of patients with rheumatoid arthritis (RA) and in controls.</p>
</caption>
<graphic xlink:href="10.1177_2042018812471070-fig1.tif"/></fig>
<p>Parathyroid hormone levels were 71.08 ± 7.02 pg/ml (mean ± SEM) (normal values 10.0–65.0 pg/ml), CRP 7.6 ± 1.57 mg/litre (normal values &lt; 3 mg/litre) and ESR 38.0 ± 4.6 mm/h in the group of patients with RA. The DAS28 index was 4.26 ± 0.26 in this group.</p>
<p>Levels of 25(OH)D<sub>3</sub> were found to be negatively correlated to the DAS28 score, the correlation coefficient being <bold>–</bold>0.084, <italic>r</italic> being 0.084 (<xref ref-type="fig" rid="fig2-2042018812471070">Figure 2</xref>). Levels of 25(OH)D<sub>3</sub> were also found to be negatively correlated to CRP (<xref ref-type="fig" rid="fig3-2042018812471070">Figure 3</xref>) and ESR (<xref ref-type="fig" rid="fig4-2042018812471070">Figure 4</xref>), the correlation coefficient being <bold>–</bold>0.115 and −0.18 and <italic>r</italic> being 0.115 and 0.18, respectively.</p>
<fig id="fig2-2042018812471070" position="float">
<label>Figure 2.</label>
<caption>
<p>Scatterplot of 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] in relation to the 28-joint Disease Activity Score (DAS28) index in the group of patients with rheumatoid arthritis (RA).</p>
</caption>
<graphic xlink:href="10.1177_2042018812471070-fig2.tif"/></fig>
<fig id="fig3-2042018812471070" position="float">
<label>Figure 3.</label>
<caption>
<p>Scatterplot of 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] (ng/ml) in relation to C-reactive protein (CRP) (mg/litre) in the group of patients with rheumatoid arthritis (RA).</p>
</caption>
<graphic xlink:href="10.1177_2042018812471070-fig3.tif"/></fig>
<fig id="fig4-2042018812471070" position="float">
<label>Figure 4.</label>
<caption>
<p>Scatterplot of 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] in relation to erythrocyte sedimentation rate (ESR) (mm/h) in the group of patients with rheumatoid arthritis (RA).</p>
</caption>
<graphic xlink:href="10.1177_2042018812471070-fig4.tif"/></fig>
</sec>
<sec id="section8-2042018812471070" sec-type="discussion">
<title>Discussion</title>
<p>In the present study vitamin D levels were found to be low in a group of patients with RA. Vitamin D levels were found to be negatively correlated with disease activity in RA.</p>
<p>Vitamin D levels have been studied in RA. Vitamin D deficiency may be associated with an increased risk for the development of RA. The Iowa Women’s Health Study by Merlino and colleagues analyzed data from a prospective cohort study of 29,368 women aged 55–69 years [<xref ref-type="bibr" rid="bibr31-2042018812471070">Merlino <italic>et al</italic>. 2004</xref>]. Merlino and colleagues found that greater intake of vitamin D might be associated with a lower risk of RA. Through 11 years of follow up, 152 cases of RA were reported. Greater intake of vitamin D was found to be inversely associated with risk of RA. Inverse associations were apparent for both dietary and supplemental vitamin D. In contrast, in two cohort studies conducted by Costenbader and colleagues vitamin D intake was not found to be associated with the risk of RA [<xref ref-type="bibr" rid="bibr11-2042018812471070">Costenbader <italic>et al</italic>. 2008</xref>]. The first cohort included 91,739 women followed from 1980 to 2002 in the Nurses’ Health Study, and the second included 94,650 women followed from 1991 to 2001 in the Nurses’ Health Study II. They observed no associations between cumulative average vitamin D intake and the risk of RA. In a meta-analysis of studies assessing the association between vitamin D intake and the risk of RA Song and colleagues showed an association between vitamin D intake and RA incidence without between study heterogeneity [<xref ref-type="bibr" rid="bibr35-2042018812471070">Song <italic>et al</italic>. 2012</xref>]. The cohort studies considered included 215,757 participants and 874 cases of RA. Individuals in the highest group for total vitamin D intake were found to have a 24.2% lower risk of developing RA than those in the lowest group. Subgroup meta-analysis also showed a significant association between vitamin D supplement intake and RA incidence. By contrast, a recent study did not find an association between vitamin D intake and the risk of RA [<xref ref-type="bibr" rid="bibr3-2042018812471070">Baker <italic>et al</italic>. 2012</xref>]. In the present study, lower levels of vitamin D compared with a control group were observed in a cohort of patients with RA.</p>
<p>In the present study an inverse association was observed between vitamin D levels and RA disease activity. Several studies have evaluated the association between vitamin D levels and RA activity. In a study involving 1191 patients with RA and 1019 controls, Rossini and colleagues found an inverse association between vitamin D levels and disease activity in RA [<xref ref-type="bibr" rid="bibr33-2042018812471070">Rossini <italic>et al</italic>. 2010</xref>]. Welsh and colleagues and Kerr and colleagues found that vitamin D deficiency is linked with disease activity in RA [<xref ref-type="bibr" rid="bibr38-2042018812471070">Welsh <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr25-2042018812471070">Kerr <italic>et al</italic>. 2011</xref>]. Also Cutolo and colleagues and Haque and Bartlett found an inverse relationship between vitamin D levels and disease activity in RA [<xref ref-type="bibr" rid="bibr13-2042018812471070">Cutolo <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr17-2042018812471070">Haque and Bartlett, 2010</xref>]. By contrast, others did not find a relationship between vitamin D deficiency and disease activity in RA [<xref ref-type="bibr" rid="bibr12-2042018812471070">Craig <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr7-2042018812471070">Braun-Moscovici <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr3-2042018812471070">Baker <italic>et al</italic>. 2012</xref>]. In the study by Braun-Moscovici and colleagues they found no correlation between vitamin D levels and disease activity among 85 patients with RA [<xref ref-type="bibr" rid="bibr7-2042018812471070">Braun-Moscovici <italic>et al</italic>. 2011</xref>]. However, overall, their subjects had high disease activity and low 25(OH)D<sub>3</sub> levels, accounting for a high vitamin D deficiency rate, which might have influenced the study outcome and the lack of correlation with disease activity. Given the increased risk for the development of cardiovascular disease in RA, Haque and colleagues further investigated the matter and found an association of vitamin D deficiency with cardiometabolic risk factors in RA [<xref ref-type="bibr" rid="bibr18-2042018812471070">Haque <italic>et al</italic>. 2012</xref>].</p>
<p>Vitamin D is known to induce immunologic tolerance [<xref ref-type="bibr" rid="bibr37-2042018812471070">Weiss, 2011</xref>]. Thus, vitamin D deficiency may perturb immune tolerance and induce the development of autoimmune diseases, such as RA. Vitamin D has immunomodulatory properties, acting on the immune system both in an endocrine and in a paracrine manner [<xref ref-type="bibr" rid="bibr20-2042018812471070">Hewison, 2012</xref>; <xref ref-type="bibr" rid="bibr32-2042018812471070">Mora <italic>et al</italic>. 2008</xref>]. It appears to regulate the immune response by a variety of mechanisms, such as decreasing antigen presentation [<xref ref-type="bibr" rid="bibr4-2042018812471070">Bartels <italic>et al</italic>. 2010</xref>], inhibiting the proinflammatory T helper type 1 profile [<xref ref-type="bibr" rid="bibr24-2042018812471070">Jirapongsananuruk <italic>et al</italic>. 2000</xref>] and inducing regulatory T cells [<xref ref-type="bibr" rid="bibr10-2042018812471070">Correale <italic>et al</italic>. 2009</xref>]. 1,25(OH)<sub>2</sub>D<sub>3</sub> suppresses proliferation and immunoglobulin production and retards differentiation of B-cell precursors into plasma cells [<xref ref-type="bibr" rid="bibr8-2042018812471070">Chen <italic>et al</italic>. 2007</xref>]. These data support a role for vitamin D deficiency in the development and progression of autoimmune inflammatory conditions in general, and in particular RA. Earlier data from animal models indicate that the 1,25(OH)<sub>2</sub>D<sub>3</sub> metabolite and its analogues may suppress collagen-induced arthritis [<xref ref-type="bibr" rid="bibr28-2042018812471070">Larsson <italic>et al</italic>. 1998</xref>]. Other data suggest that vitamin D receptor agonists may also prevent and suppress established collagen-induced arthritis [<xref ref-type="bibr" rid="bibr1-2042018812471070">Adorini, 2005</xref>]. Having said that, however, there are data showing that vitamin D may be negatively affected in acute response, that is, its levels may decrease in the setting of inflammation, such as in active RA [<xref ref-type="bibr" rid="bibr16-2042018812471070">Galloway <italic>et al</italic>. 2000</xref>]. Despite that, treatment with rituximab in RA did not affect vitamin D levels, although it decreased indices of inflammation [<xref ref-type="bibr" rid="bibr19-2042018812471070">Hasan <italic>et al</italic>. 2012</xref>].</p>
<p>Supplementation with vitamin D has been proposed as a means to induce immune tolerance and thus prevent the development of autoimmune diseases [<xref ref-type="bibr" rid="bibr37-2042018812471070">Weiss, 2011</xref>]. Recently, the combination of antirheumatic drugs with vitamin D has been suggested for RA [<xref ref-type="bibr" rid="bibr27-2042018812471070">Kim <italic>et al</italic>. 2012</xref>]. Patients with RA are prone to osteoporosis [<xref ref-type="bibr" rid="bibr14-2042018812471070">Deal, 2012</xref>] and suffer from pain when the disease is in flare. Vitamin D supplementation has been proposed for patients with RA for the prevention and treatment of osteoporosis as well as for its possible effects on disease activity [<xref ref-type="bibr" rid="bibr36-2042018812471070">Varenna <italic>et al</italic>. 2012</xref>].</p>
<p>In conclusion, it appears that vitamin D deficiency is highly prevalent in patients with RA, and that vitamin D deficiency may be linked to disease severity in RA. As vitamin D deficiency has been linked to diffuse musculoskeletal pain, these results have therapeutic implications. Vitamin D supplementation may be needed for the prevention of osteoporosis and for pain relief in patients with RA.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adorini</surname><given-names>L.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Intervention in autoimmunity: the potential of vitamin D receptor agonists</article-title>. <source>Cell Immunol</source> <volume>233</volume>: <fpage>115</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr2-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aletaha</surname><given-names>D.</given-names></name>
<name><surname>Neogi</surname><given-names>T.</given-names></name>
<name><surname>Silman</surname><given-names>A.</given-names></name>
<name><surname>Funovits</surname><given-names>J.</given-names></name>
<name><surname>Felson</surname><given-names>D.</given-names></name>
<name><surname>Bingham</surname><given-names>C.</given-names><suffix>III</suffix></name>
<etal/></person-group>. (<year>2010</year>) <article-title>2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>2569</fpage>–<lpage>2581</lpage>.</citation>
</ref>
<ref id="bibr3-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baker</surname><given-names>J.</given-names></name>
<name><surname>Baker</surname><given-names>D.</given-names></name>
<name><surname>Toedter</surname><given-names>G.</given-names></name>
<name><surname>Shults</surname><given-names>J.</given-names></name>
<name><surname>Von Feldt</surname><given-names>J.</given-names></name>
<name><surname>Leonard</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis</article-title>. <source>Clin Exp Rheumatol</source> <volume>30</volume>: <fpage>658</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr4-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartels</surname><given-names>L.</given-names></name>
<name><surname>Hvas</surname><given-names>C.</given-names></name>
<name><surname>Agnholt</surname><given-names>J.</given-names></name>
<name><surname>Dahlerup</surname><given-names>J.</given-names></name>
<name><surname>Agger</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation</article-title>. <source>Int Immunopharmacol</source> <volume>10</volume>: <fpage>922</fpage>–<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr5-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartley</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Vitamin D: emerging roles in infection and immunity</article-title>. <source>Expert Rev Anti Infect Ther</source> <volume>8</volume>: <fpage>1359</fpage>–<lpage>1369</lpage>.</citation>
</ref>
<ref id="bibr6-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bikle</surname><given-names>D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Vitamin D regulation of immune function</article-title>. <source>Vitam Horm</source> <volume>86</volume>: <fpage>1</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr7-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun-Moscovici</surname><given-names>Y.</given-names></name>
<name><surname>Toledano</surname><given-names>K.</given-names></name>
<name><surname>Markovits</surname><given-names>D.</given-names></name>
<name><surname>Rozin</surname><given-names>A.</given-names></name>
<name><surname>Nahir</surname><given-names>A.</given-names></name>
<name><surname>Balbir-Gurman</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Vitamin D level: is it related to disease activity in inflammatory joint disease?</article-title> <source>Rheumatol Int</source> <volume>31</volume>: <fpage>493</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr8-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Sims</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Lipsky</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation</article-title>. <source>J Immunol</source> <volume>179</volume>: <fpage>1634</fpage>–<lpage>1647</lpage>.</citation>
</ref>
<ref id="bibr9-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choy</surname><given-names>E.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> <volume>51</volume>(<supplement>Suppl. 5</supplement>): <fpage>v3</fpage>–<lpage>v11</lpage>.</citation>
</ref>
<ref id="bibr10-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correale</surname><given-names>J.</given-names></name>
<name><surname>Ysrraelit</surname><given-names>M.</given-names></name>
<name><surname>Gaitán</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Immunomodulatory effects of vitamin D in multiple sclerosis</article-title>. <source>Brain</source> <volume>132</volume>: <fpage>1146</fpage>–<lpage>1160</lpage>.</citation>
</ref>
<ref id="bibr11-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costenbader</surname><given-names>K.</given-names></name>
<name><surname>Feskanich</surname><given-names>D.</given-names></name>
<name><surname>Holmes</surname><given-names>M.</given-names></name>
<name><surname>Karlson</surname><given-names>E.</given-names></name>
<name><surname>Benito-Garcia</surname><given-names>E.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women</article-title>. <source>Ann Rheum Dis</source> <volume>67</volume>: <fpage>530</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr12-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craig</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Curtis</surname><given-names>J.</given-names></name>
<name><surname>Alarcón</surname><given-names>G.</given-names></name>
<name><surname>Conn</surname><given-names>D.</given-names></name>
<name><surname>Jonas</surname><given-names>B.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis</article-title>. <source>J Rheumatol</source> <volume>37</volume>: <fpage>275</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr13-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cutolo</surname><given-names>M.</given-names></name>
<name><surname>Otsa</surname><given-names>K.</given-names></name>
<name><surname>Laas</surname><given-names>K.</given-names></name>
<name><surname>Yprus</surname><given-names>M.</given-names></name>
<name><surname>Lehtme</surname><given-names>R.</given-names></name>
<name><surname>Secchi</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe</article-title>. <source>Clin Exp Rheumatol</source> <volume>24</volume>: <fpage>702</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr14-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deal</surname><given-names>C.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Bone loss in rheumatoid arthritis: systemic, periarticular, and focal</article-title>. <source>Curr Rheumatol Rep</source> <volume>14</volume>: <fpage>231</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr15-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernandes de Abreu</surname><given-names>D.</given-names></name>
<name><surname>Eyles</surname><given-names>D.</given-names></name>
<name><surname>Féron</surname><given-names>F.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases</article-title>. <source>Psychoneuroendocrinology</source> <volume>34</volume>(<supplement>Suppl. 1</supplement>): <fpage>S265</fpage>–<lpage>S277</lpage>.</citation>
</ref>
<ref id="bibr16-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galloway</surname><given-names>P.</given-names></name>
<name><surname>McMillan</surname><given-names>D.</given-names></name>
<name><surname>Sattar</surname><given-names>N.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Effect of the inflammatory response on trace element and vitamin status</article-title>. <source>Ann Clin Biochem</source> <volume>37</volume>: <fpage>289</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr17-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haque</surname><given-names>U.</given-names></name>
<name><surname>Bartlett</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis</article-title>. <source>Clin Exp Rheumatol</source> <volume>28</volume>: <fpage>745</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr18-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haque</surname><given-names>U.</given-names></name>
<name><surname>Bathon</surname><given-names>J.</given-names></name>
<name><surname>Giles</surname><given-names>J.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Association of vitamin D with cardiometabolic risk factors in rheumatoid arthritis</article-title>. <source>Arthritis Care Res (Hoboken)</source> <volume>64</volume>: <fpage>1497</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr19-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hasan</surname><given-names>E.</given-names></name>
<name><surname>Olusi</surname><given-names>S.</given-names></name>
<name><surname>Al-Awadhi</surname><given-names>A.</given-names></name>
<name><surname>Mokaddem</surname><given-names>K.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>George</surname><given-names>S.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis</article-title>. <source>Biologics</source> <volume>6</volume>:<fpage>31</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr20-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hewison</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Vitamin D and immune function: autocrine, paracrine or endocrine?</article-title> <source>Scand J Clin Lab Invest Suppl</source> <volume>243</volume>: <fpage>92</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr21-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirani</surname><given-names>V.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Vitamin D status and pain: analysis from the Health Survey for England among English adults aged 65 years and over</article-title>. <source>Br J Nutr</source> <volume>107</volume>: <fpage>1080</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr22-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holick</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Vitamin D: evolutionary, physiological and health perspectives</article-title>. <source>Curr Drug Targets</source> <volume>12</volume>: <fpage>4</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr23-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jankosky</surname><given-names>C.</given-names></name>
<name><surname>Deussing</surname><given-names>E.</given-names></name>
<name><surname>Gibson</surname><given-names>R.</given-names></name>
<name><surname>Haverkos</surname><given-names>H.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Viruses and vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis</article-title>. <source>Virus Res</source> <volume>163</volume>: <fpage>424</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr24-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jirapongsananuruk</surname><given-names>O.</given-names></name>
<name><surname>Melamed</surname><given-names>I.</given-names></name>
<name><surname>Leung</surname><given-names>D.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses</article-title>. <source>J Allergy Clin Immunol</source> <volume>106</volume>: <fpage>981</fpage>–<lpage>985</lpage>.</citation>
</ref>
<ref id="bibr25-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kerr</surname><given-names>G.</given-names></name>
<name><surname>Sabahi</surname><given-names>I.</given-names></name>
<name><surname>Richards</surname><given-names>J.</given-names></name>
<name><surname>Caplan</surname><given-names>L.</given-names></name>
<name><surname>Cannon</surname><given-names>G.</given-names></name>
<name><surname>Reimold</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity</article-title>. <source>J Rheumatol</source> <volume>38</volume>: <fpage>53</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr26-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keystone</surname><given-names>E.</given-names></name>
<name><surname>Smolen</surname><given-names>J.</given-names></name>
<name><surname>van Riel</surname><given-names>P.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Developing an effective treatment algorithm for rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> <volume>51</volume>(<supplement>Suppl. 5</supplement>): <fpage>v48</fpage>–<lpage>v54</lpage>.</citation>
</ref>
<ref id="bibr27-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Choi</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Ji</surname><given-names>J.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis</article-title>. <source>Med Hypotheses</source> <volume>79</volume>: <fpage>757</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr28-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larsson</surname><given-names>P.</given-names></name>
<name><surname>Mattsson</surname><given-names>L.</given-names></name>
<name><surname>Klareskog</surname><given-names>L.</given-names></name>
<name><surname>Johnsson</surname><given-names>C.</given-names></name>
</person-group> (<year>1998</year>) <article-title>A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia</article-title>. <source>Clin Exp Immunol</source> <volume>114</volume>: <fpage>277</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr29-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>R.</given-names></name>
<name><surname>Sequeira</surname><given-names>V.</given-names></name>
<name><surname>Gordon-Thomson</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Vitamin D: the light side of sunshine</article-title>. <source>Eur J Clin Nutr</source> <volume>65</volume>: <fpage>986</fpage>–<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr30-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McInnes</surname><given-names>I.</given-names></name>
<name><surname>Schett</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The pathogenesis of rheumatoid arthritis</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>2205</fpage>–<lpage>2219</lpage>.</citation>
</ref>
<ref id="bibr31-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merlino</surname><given-names>L.</given-names></name>
<name><surname>Curtis</surname><given-names>J.</given-names></name>
<name><surname>Mikuls</surname><given-names>T.</given-names></name>
<name><surname>Cerhan</surname><given-names>J.</given-names></name>
<name><surname>Criswell</surname><given-names>L.</given-names></name>
<name><surname>Saag</surname><given-names>K.</given-names></name>
</person-group>; <collab>Iowa Women’s Health Study</collab> (<year>2004</year>) <article-title>Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>72</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr32-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mora</surname><given-names>J.R.</given-names></name>
<name><surname>Iwata</surname><given-names>M.</given-names></name>
<name><surname>von Andrian</surname><given-names>U.H.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Vitamin effects on the immune system: vitamins A and D take centre stage</article-title>. <source>Nat Rev Immunol</source> <volume>8</volume>: <fpage>685</fpage>–<lpage>698</lpage>.</citation>
</ref>
<ref id="bibr33-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossini</surname><given-names>M.</given-names></name>
<name><surname>Maddali Bongi</surname><given-names>S.</given-names></name>
<name><surname>La Montagna</surname><given-names>G.</given-names></name>
<name><surname>Minisola</surname><given-names>G.</given-names></name>
<name><surname>Malavolta</surname><given-names>N.</given-names></name>
<name><surname>Bernini</surname><given-names>L.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability</article-title>. <source>Arthritis Res Ther</source> <volume>12</volume>: <fpage>R216</fpage>.</citation>
</ref>
<ref id="bibr34-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Pathak</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Are biological targets the final goal for rheumatoid arthritis therapy?</article-title> <source>Expert Opin Biol Ther</source> <volume>12</volume>: <fpage>1611</fpage>–<lpage>1622</lpage>.</citation>
</ref>
<ref id="bibr35-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Bae</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis</article-title>. <source>Clin Rheumatol</source> <day>2</day> <month>September</month> [Epub ahead of print].</citation>
</ref>
<ref id="bibr36-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varenna</surname><given-names>M.</given-names></name>
<name><surname>Manara</surname><given-names>M.</given-names></name>
<name><surname>Cantatore</surname><given-names>F.</given-names></name>
<name><surname>Del Puente</surname><given-names>A.</given-names></name>
<name><surname>Di Munno</surname><given-names>O.</given-names></name>
<name><surname>Malavolta</surname><given-names>N.</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis</article-title>. <source>Clin Exp Rheumatol</source> <volume>30</volume>: <fpage>714</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr37-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic?</article-title> <source>J Allergy Clin Immunol</source> <volume>127</volume>: <fpage>1128</fpage>–<lpage>1130</lpage>.</citation>
</ref>
<ref id="bibr38-2042018812471070">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Welsh</surname><given-names>P.</given-names></name>
<name><surname>Peters</surname><given-names>M.</given-names></name>
<name><surname>McInnes</surname><given-names>I.</given-names></name>
<name><surname>Lems</surname><given-names>W.</given-names></name>
<name><surname>Lips</surname><given-names>P.</given-names></name>
<name><surname>McKellar</surname><given-names>G.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1165</fpage>–<lpage>1167</lpage>.</citation>
</ref></ref-list>
</back>
</article>